Abstract
The expression of PINX1, a possible telomerase inhibitor and a putative tumor suppressor, has not been studied in human cancers, including gastric cancer (GC). We examined expression of PINX1 by quantitative reverse transcription (RT)–PCR in 73 cases of GC, and 45 of these cases were further studied for loss of heterozygosity (LOH) by PCR with microsatellite marker D8S277. Reduced expression (tumor vs normal ratio<0.5) of PINX1 was detected in 50 (68.5%) of 73 cases of GC. GC tissues with reduced expression of PINX1 showed significantly higher telomerase activities as measured by telomeric repeat amplification protocol than those with normal expression of PINX1 (P = 0.031). LOH of PINX1 locus was detected in 15 (33.3%) of 45 cases of GC and was correlated significantly with reduced expression of PINX1 (P=0.031). Expression of PINX1 in a GC cell line, MKN-74, was induced by treatment with trichostatin A (TSA) or nicotinamide (NAM). Chromatin immunoprecipitation assay of MKN-74 cells revealed that acetylation of histone H4 in the 5′ untranslated region (UTR) of PINX1 was enhanced by treatment with TSA or NAM, whereas acetylation of histone H3 was not changed by TSA or NAM. In addition, TSA or NAM treatment led to inhibition of telomerase activity in MKN-74 cells. These results indicate that LOH of PINX1 locus and hypoacetylation of histone H4 in the 5′ UTR of PINX1 are associated with reduced expression of PINX1 in GC.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Akiyama Y, Maesawa C, Wada K, Fujisawa K, Itabashi T, Noda Y, Honda T, Sato N, Ishida K, Takagane A, Saito K and Masuda T . (2004). Oncol. Rep., 11, 871–874.
Artandi SE, Chang S, Lee SL, Alson S, Gottlieb GJ, Chin L and DePinho RA . (2000). Nature, 406, 641–645.
Baffa R, Santoro R, Bullrich F, Mandes B, Ishii H and Croce CM . (2000). Clin. Cancer Res., 6, 1372–1377.
Bitterman KJ, Anderson RM, Cohen HY, Latorre-Esteves M and Sinclair DA . (2002). J. Biol. Chem., 277, 45099–45107.
Chin L, Artandi SE, Shen Q, Tam A, Lee SL, Gottlieb GJ, Greider CW and DePinho RA . (1999). Cell, 97, 527–538.
Cong YS, Wright WE and Shay JW . (2002). Microbiol. Mol. Biol. Rev., 66, 407–425.
DePinho RA . (2000). Nature, 408, 248–254.
Emi M, Fujiwara Y, Nakajima T, Tsuchiya E, Tsuda H, Hirohashi S, Maeda Y, Tsuruta K, Miyaki M and Nakamura Y . (1992). Cancer Res., 52, 5368–5372.
Ferreira R, Naguibneva I, Mathieu M, Ait-Si-Ali S, Robin P, Pritchard LL and Harel-Bellan A . (2001). EMBO Rep., 2, 794–799.
Fujiwara Y, Emi M, Ohata H, Kato Y, Nakajima T, Mori T and Nakamura Y . (1993). Cancer Res., 53, 1172–1174.
Grunstein M . (1997). Nature, 389, 349–352.
Hamai Y, Oue N, Mitani Y, Nakayama H, Ito R, Matsusaki K, Yoshida K, Toge T and Yasui W . (2003). Cancer Sci., 94, 692–698.
Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB . (1996). Proc. Natl. Acad. Sci. USA, 93, 9821–9826.
Imai S, Armstrong CM, Kaeberlein M and Guarente L . (2000). Nature, 403, 795–800.
Jones PA and Baylin SB . (2002). Nat. Rev. Genet., 3, 415–428.
Kass SU, Pruss D and Wolffe AP . (1997). Trends Genet., 13, 444–449.
Kondo T, Oue N, Yoshida K, Mitani Y, Naka K, Nakayama H and Yasui W . (2004). Cancer Res., 64, 523–529.
Kuniyasu H, Domen T, Hamamoto T, Yokozaki H, Yasui W, Tahara H and Tahara E . (1997). Jpn. J. Cancer Res., 88, 103–107.
Landry J, Sutton A, Tafrov ST, Heller RC, Stebbins J, Pillus L and Sternglanz R . (2000). Proc. Natl. Acad. Sci. USA, 97, 5807–5811.
Lauren P . (1965). Acta. Pathol. Microbiol. Scand., 64, 31–49.
Liao C, Zhao M, Song H, Uchida K, Yokoyama KK and Li T . (2000). Hepatology, 32, 721–727.
Liao C, Zhao MJ, Zhao J, Jia D, Song H and Li ZP . (2002). World J. Gastroentrol., 8, 1050–1052.
Liao C, Zhao MJ, Zhao J, Song H, Pineau P, Marchio A, Dejean A, Tiollais P, Wang HY and Li TP . (2003). World J. Gastroentrol., 9, 89–93.
Liloglou T, Maloney P, Xinarianos G, Fear S and Field JK . (2000). Int. J. Oncol., 16, 5–14.
Liloglou T, Maloney P, Xinarianos G, Hulbert M, Walshaw MJ, Gosney JR, Turnbull L and Field JK . (2001). Cancer Res., 61, 1624–1628.
Luger K, Mader AW, Richmond RK, Sargent DF and Richmond TJ . (1997). Nature, 389, 251–260.
Luger K and Richmond TJ . (1998). Curr. Opin. Genet. Dev., 8, 140–146.
Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L and Gu W . (2001). Cell, 107, 137–148.
Macoska JA, Trybus TM, Benson PD, Sakr WA, Grignon DJ, Wojno KD, Pietruk T and Powell IJ . (1995). Cancer Res., 55, 5390–5395.
Meeker AK, Hicks JL, Platz EA, March GE, Bennett CJ, Delannoy MJ and De Marzo AM . (2002). Cancer Res., 62, 6405–6409.
North BJ, Marshall BL, Borra MT, Denu JM and Verdin E . (2003). Mol. Cell, 11, 437–444.
Ochiai A, Yasui W and Tahara E . (1985). Jpn. J. Cancer Res., 76, 1064–1071.
Ohata H, Emi M, Fujiwara Y, Higashino K, Nakagawa K, Futagami R, Tsuchiya E and Nakamura Y . (1993). Genes Chromosomes Cancer, 7, 85–88.
Oshimo Y, Oue N, Mitani Y, Nakayama H, Kitadai Y, Yoshida K, Chayama K and Yasui W . (2004). Int. J. Cancer, 110, 212–218.
O’Sullivan JN, Bronner MP, Brentnall TA, Finley JC, Shen WT, Emerson S, Emond MJ, Gollahon KA, Moskovitz AH, Crispin DA, Potter JD and Rabinovitch PS . (2002). Nat. Genet., 32, 280–284.
Oue N, Hamai Y, Mitani Y, Matsumura S, Oshimo Y, Aung PP, Kuraoka K, Nakayama H and Yasui W . (2004). Cancer Res., 64, 2397–2405.
Oue N, Matsumura S, Nakayama H, Kitadai Y, Taniyama K, Matsusaki K and Yasui W . (2003). Oncology, 64, 423–429.
Oue N, Motoshita J, Yokosaki H, Hayashi K, Tahara E, Taniyama K, Matsusaki K and Yasui W . (2002). J. Pathol., 198, 55–59.
Oue N, Shigeishi H, Kuniyasu H, Yokosaki H, Kuraoka K, Ito R and Yasui W . (2001). Int. J. Cancer, 93, 805–809.
Park WS, Lee JH, Park JY, Jeong SW, Shin MS, Kim HS, Lee SK, Lee SN, Lee SH, Park CG, Yoo NJ and Lee JY . (2002). Cancer Lett., 178, 199–207.
Razin A and Cedar H . (1991). Microbil. Rev., 55, 451–458.
Shay JW and Bacchetti S . (1997). Eur. J. Cancer, 33, 787–791.
Smith JS, Brachmann CB, Celic I, Kenna MA, Muhammad S, Starai VJ, Avalos JL, Escalante-Semerena JC, Grubmeyer C, Wolberger C and Boeke JD . (2000). Proc. Natl. Acad. Sci. USA, 97, 6658–6663.
Sobin LH and Wittekind CH (ed). (1997). TNM Classification of Malignant Tumors 5th edn. Wiley-Liss, Inc: New York, pp. 59–62.
Suzuki T, Yokozaki H, Kuniyasu H, Hayashi K, Naka K, Ono S, Ishikawa T, Tahara E and Yasui W . (2000). Int. J. Cancer, 88, 992–997.
Tahara H, Kuniyasu H, Yokosaki H, Yasui W, Shay JW, Ide T and Tahara E . (1995). Clin. Cancer Res., 1, 1245–1251.
Van Heek NT, Meeker AK, Kern SE, Yeo CJ, Lillemoe KD, Cameron JL, Offerhaus GL, Hicks JL, Wilentz RE, Goggins MG, De Marzo AM, Hruban RH and Maitra A . (2002). Am. J. Pathol., 161, 1541–1547.
Yanagihara K, Seyama T, Tsumuraya M, Kamada N and Yokoro K . (1991). Cancer Res., 51, 381–386.
Yaremko ML, Recant WM and Westbrook CA . (1995). Genes Chromosomes Cancer, 13, 186–191.
Yasui W, Tahara E, Tahara H, Fujimoto J, Naka K, Nakayama J, Ishikawa F, Ide T and Tahara E . (1999). Jpn. J. Cancer Res., 90, 589–595.
Yasui W, Tahara H, Tahara E, Fujimoto J, Nakayama J, Ishikawa F, Ide T and Tahara E . (1998). Jpn. J. Cancer Res., 89, 1099–1103.
Yasui W, Yokozaki H, Fujimoto J, Naka K, Kuniyasu H and Tahara E . (2000). J. Gastroenterol., 35, 111–115.
Yustein AS, Harper JC, Petroni GR, Cummings OW, Moskaluk CA and Powell SM . (1999). Cancer Res., 59, 1437–1441.
Zhou XZ and Lu KP . (2001). Cell, 107, 347–359.
Acknowledgements
We thank Mr M Takatani and Ms M Ueda for their excellent technical assistance and advice.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kondo, T., Oue, N., Mitani, Y. et al. Loss of heterozygosity and histone hypoacetylation of the PINX1 gene are associated with reduced expression in gastric carcinoma. Oncogene 24, 157–164 (2005). https://doi.org/10.1038/sj.onc.1207832
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207832
Keywords
This article is cited by
-
PinX1 represses renal cancer angiogenesis via the mir-125a-3p/VEGF signaling pathway
Angiogenesis (2019)
-
The depletion of PinX1 involved in the tumorigenesis of non-small cell lung cancer promotes cell proliferation via p15/cyclin D1 pathway
Molecular Cancer (2017)
-
PinX1 inhibits cell proliferation, migration and invasion in glioma cells
Medical Oncology (2015)
-
Reduced expression of PinX1 correlates to progressive features in patients with prostate cancer
Cancer Cell International (2014)
-
Gene expression levels of human shelterin complex and shelterin-associated factors regulated by the topoisomerase II inhibitors doxorubicin and etoposide in human cultured cells
Tumor Biology (2013)